Nitracrine

Nitracrine inhibits RNA synthesis and covalently, reversibly binds to DNA but also forms covalent adducts with DNA in vivo. Nitracrine, a 1-nitroacridine derivative, is a potent hypoxia-selective agent in vitro and antitumor agent. Nitracrine has cytotoxicity towards most cells[1][2][3].

Product Specifications

CAS Number

[4533-39-5]

UNSPSC

12352005

Hazard Statement

H302, H315, H319, H335

Target

DNA/RNA Synthesis

Type

Reference compound

Related Pathways

Cell Cycle/DNA Damage

Applications

Cancer-programmed cell death

Field of Research

Cancer

Assay Protocol

https://www.medchemexpress.com/Nitracrine.html

Purity

97.76

Solubility

DMSO : 100 mg/mL (ultrasonic)

Smiles

O=[N+](C1=CC=CC2=NC3=CC=CC=C3C(NCCCN(C)C)=C21)[O-]

Molecular Formula

C18H20N4O2

Molecular Weight

324.38

Precautions

H302, H315, H319, H335

References & Citations

[1]Wilson WR, et al. Selective toxicity of nitracrine to hypoxic mammalian cells. Br J Cancer. 1984 Feb;49 (2) :215-23.|[2]Gniazdowski M, et al. Nitracrine and its congeners--an overview. Gen Pharmacol. 1995 May;26 (3) :473-81.|[3]Daghastanli NA, et al. Cytotoxicity of nitroheterocyclic compounds, quinifuryl and nitracrine, towards leukaemic and normal cells on the dark and under illumination with visible light. J Photochem Photobiol B. 2004 Jul 19;75 (1-2) :27-32.